Inventiva S.A.

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases. Its lead product candidate is Lanifibranor, a novel peroxisome proliferator-activated receptor agonist currently in the NATiV3 Phase 3 clinical trial for treating adult patients with MASH. The company also develops Odiparcil for mucopolysaccharidoses and a pre-clinical TGF-ß program for idiopathic pulmonary fibrosis. Inventiva operates globally, with a presence in France and other international markets.

Inventiva S.A. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol IVA. Its shares trade in US dollars (USD). The company is headquartered in Daix, France, and its listing on a US exchange provides access to American investors.

Inventiva S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing innovative therapies for diseases with high unmet medical needs, particularly metabolic dysfunction-associated steatohepatitis (MASH) and rare genetic disorders.

Inventiva S.A. is headquartered in Daix, France, and serves markets in France and globally. The company was incorporated in 2011 and has since been developing therapies for patients worldwide. Its clinical trials, such as the NATiV3 Phase 3 trial for Lanifibranor, involve international sites, reflecting its global reach in addressing diseases like MASH and mucopolysaccharidoses.